SHANGHAI, Feb. 02, 2026 (GLOBE NEWSWIRE) — Headquartered in Shanghai, Arctic Vision (Cayman) Limited (“Arctic Vision”), a global ophthalmic company, announced that it has entered into an agreement to acquire the innovative ophthalmic device business of MDCO Technology, a Hangzhou-based ophthalmic medical-device company.
The proposed transaction will bring MDCO’s premium intraocular lens (IOL), implantable contact lens (Phakic Lens), and refractive-device platforms into Arctic Vision’s global ophthalmic innovation framework. It strengthens Arctic Vision’s global ophthalmic business by integrating advanced device engineering and intelligent manufacturing with its existing innovation capabilities.
Accelerating Ophthalmic Innovation Globally across Drug & Device
The proposed transaction aligns with the long-term strategy of Arctic Vision, expanding the company’s pipeline with innovative therapeutics with high unmet need.
The transaction is expected to create an industry-leading pipeline, building on Arctic Vision’s deep R&D capabilities in retinal, ocular surface, and neuro-ophthalmic areas, together with MDCO’s design and manufacturing expertise in IOL and Phakic Lens.
Under the terms of the transactions, MDCO will become a wholly owned subsidiary of Arctic Vision. The group will maintain key operations in Shanghai (biopharmaceutical R&D and regulatory affairs, operations), Hangzhou (implanted device R&D, manufacturing and commercial management), and California (design and global collaboration).
Leadership Perspectives
“This transaction represents a pivotal step for Arctic Vision’s long-term growth strategy,” said Dr. Eddy Wu, Founder, Chairman and CEO of Arctic Vision. “Through the integration of MDCO’s ophthalmic device platforms with Arctic Vision’s pharmaceutical innovation capabilities, we are establishing a truly comprehensive ophthalmic innovation ecosystem—one that integrates scientific excellence with advanced manufacturing and commercial scale. Looking ahead, we are building a company structurally prepared for broader global investment participation and future capital-market opportunities, while expanding our ability to reach more patients and deliver greater impact across the ophthalmology community worldwide.”
“Becoming part of Arctic Vision’s integrated platform opens a new chapter for MDCO,” said Mr. Liang Liu, Chairman of MDCO Technology. “MDCO’s hallmark intraocular and refractive products will benefit from Arctic Vision’s strong R&D and regulatory foundation, enabling accelerated development and broader market access worldwide.”
